Boehringer Ingelheim Supports American Lung Association's Bronchiectasis Education Campaign
Boehringer Ingelheim has partnered with the American Lung Association to launch a new educational campaign aimed at improving the management of bronchiectasis, a chronic lung disease characterized by widened and scarred airways. The initiative, which coincides with World Bronchiectasis Day, seeks to empower patients with knowledge and resources to better cope with their condition.
Campaign Objectives and Resources
The campaign, launched on July 2, 2025, provides patients with access to a range of resources designed to enhance their understanding and management of bronchiectasis. These materials include:
- Information on managing disease flare-ups
- Guidance on coping with the psychological impact of the condition
- Exploration of available treatment options
Harold Wimmer, CEO of the American Lung Association, emphasized the importance of the initiative, stating, "While there is currently no cure for bronchiectasis, early diagnosis, effective management and a solid support system can help people with the disease lead healthy and active lives."
Pharmaceutical Industry Developments
The launch of this educational campaign comes at a critical time for the bronchiectasis field, with several pharmaceutical companies making significant strides in drug development:
Insmed's Brensocatib
Insmed is awaiting an FDA decision on its DPP-1 inhibitor, brensocatib, expected next month. If approved, the company plans to immediately launch the drug in the U.S. market.
Boehringer Ingelheim's Research
Boehringer Ingelheim, in addition to supporting the educational campaign, is advancing its own DPP-1 inhibitor through clinical trials. The company initiated a phase 3 trial last month, with study completion anticipated in 2028.
Other Industry Players
- Haisco Pharmaceutical is conducting a phase 3 trial of another DPP-1 inhibitor in China.
- Chiesi Farmaceutici licensed Haisco's candidate for development outside Greater China in 2023 and is currently running a phase 1/2 trial.
As the pharmaceutical industry continues to invest in bronchiectasis research and development, educational initiatives like the American Lung Association's campaign play a crucial role in supporting patients and raising awareness about this challenging condition.
References
- Boehringer backs education drive to improve bronchiectasis management
Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a push to educate people with bronchiectasis about how to better manage the disease.
Explore Further
What are the expected efficacy and safety results for Insmed's brensocatib from its impending FDA decision?
How does Boehringer Ingelheim's DPP-1 inhibitor progress compare with the clinical milestones of its competitors?
What is the current market size for bronchiectasis treatments in the U.S., and how might it change with new drug approvals?
What are the key differences in study design and expected outcomes between Boehringer Ingelheim’s and Haisco Pharmaceutical's DPP-1 inhibitor trials?
What competitive advantages might Chiesi Farmaceutici's licensed DPP-1 inhibitor candidate offer in markets outside Greater China?